Research programme: 13-valent and 23-valent pneumococcal vaccines - Chongqing Zhifei Biological ProductsAlternative Names: 13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine
Latest Information Update: 16 Jul 2016
At a glance
- Originator Chongqing Zhifei Biological Products
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Pneumococcal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumococcal-infections in China (Parenteral, Injection)
- 29 Oct 2012 Preclinical trials in Pneumococcal infections in China (Parenteral)